YNIOS PHARMA is developing TA64, in a sterile, injectable compound administered by perfusion, designed to protect against organ failure by stabilizing vascular integrity and precisely modulating the innate immune response. TA64 is formulated for easy sterilization and scalable manufacturing, ensuring suitability for urgent deployment in critical care settings. Its mechanism of action addresses the core drivers of multi-organ dysfunction — including immune overactivation, endothelial damage, and microcirculatory failure — positioning it as a novel intervention in intensive care medicine.

Our development strategy is focused, scalable, and indication-driven. The initial target  is septic shock, a high-mortality condition with no approved targeted therapies. This lead indication serves as the foundation for strategic label expansion into a wider group of critical care syndromes that share overlapping pathophysiology. These include acute respiratory failure syndromes (such as ARDS, severe COVID-19, and influenza), systemic inflammatory conditions (like SIRS and early sepsis), and trauma- or burn-induced critical illness. By demonstrating clinical efficacy in septic shock, we aim to unlock the broader potential of TA64 as a platform therapy across multiple ICU indications — all unified by the same path to organ failure.